# lt3001-report
Comprehensive investment analysis of LT3001 (Lumosa Therapeutics 6535.TW) -  A breakthrough thrombolytic peptide for acute ischemic stroke with 24-hour  treatment window and unprecedented 0% intracranial hemorrhage rate.
